

HB 6095 – Scheduling of Drug Products Containing Cannabidiol (Identical SB 1476)

This bill amends s. 893.03, F.S., deleting the following from Schedule V substances: “A drug product in finished dosage formulation that has been approved by the United States Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.” Since all penalties for Schedule V drugs under s. 893.13, F.S. are misdemeanors, there would not be an impact on the prison population.

CONFERENCE ADOPTED ESTIMATE: No Impact

Requested by: Senate